Skip to primary content
Skip to secondary content

Biotech 365

Main menu

  • Biotech 365
  • Companies
  • Healthcare Investors
    • Healthcare LPs
  • Healthcare Investors Matchmaking
  • Free DEMO
  • Services
    • Preclinical Studies Database
    • Scientific Due Diligence
    • CRO & CDMO Database
  • Contact

Tag Archives: Alan Musso

Bellicum – dendritic cell vaccines

Posted on by

Bellicum Pharmaceuticals is a biopharma company developing novel cellular immunotherapies for various forms of cancer (both hematological and solid tumors), as well as orphan inherited blood disorders.

Bellicum – dendritic cell vaccines

Bellicum Continue reading →

Posted in Biotech Companies, Biotech Companies USA | Tagged activation switch, Alan Musso, Annemarie Moseley, Bellicum, Bellicum - dendritic cell vaccines, Bellicum Pharmaceuticals, BPX-201, BPX-401, BPX-501, BPX-601, BPX-701, cancer immunotherapies, cancer immunotherapy, CAR T cell therapy, CaspaCIDe, CD40, cellular immunotherapies, cellular immunotherapy, Chemical Induction Dimerization, Chemical Induction of Dimerization, CID, CIDeCAR, David Spencer, DeCIDe, dendritic cell, dendritic cell therapies, dendritic cell therapy, dendritic cell vaccine, dendritic cell vaccines, dendritic cells, dual co-stimulatory domain, Frank McGuyer, GoCAR-T, hematological tumor, hematological tumors, hematopoietic stem cell transplantation, HSCT, immunotherapies, immunotherapy, James Brown, Joe Senesac, Jon Stonehouse, Ken Moseley, Kevin Slawin, MyD88, orphan inherited blood disorder, orphan inherited blood disorders, Peter Hoang, Reid Huber, rimiducid, safety switch, solid tumor, solid tumors, Thomas Farrell, Tom Farrell

        Services              Healthcare Investors Database              FAQs               CGU               Biotech & Pharma News             Contact
Proudly powered by WordPress